Mutation News and Research

RSS

A potential epigenetic 'on-off' switch for cancer

A team of Boston University School of Medicine (BUSM) researchers have proposed that an "on and off" epigenetic switch could be a common mechanism behind the development of different types of cancer. Epigenetics is the phenomena whereby genetically identical cells express their genes differently, resulting in different physical traits.

15 May 2014

Link found between antibiotic use in babies and asthma

New research has shed light on how treating babies with antibiotics may lead to an increased risk for asthma.

15 May 2014

Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

The International Society for Autism Research (INSAR), a scientific and professional organization devoted to advancing knowledge about autism spectrum disorders, convened more than 1700 researchers, delegates, autism specialists and students from 40 countries for the 13th Annual International Meeting for Autism Research (IMFAR), the world's largest scientific gathering on autism research, from May 15 through May 17 at the Atlanta Marriott Marquis in Atlanta, GA.

15 May 2014

Suppressing hyperactivity of calcium channels alleviates familial Alzheimer's disease

In 2008, researchers at the Perelman School of Medicine at the University of Pennsylvania showed that mutations in two proteins associated with familial Alzheimer's disease (FAD) disrupt the flow of calcium ions within neurons.

15 May 2014

Tubal ligation and breastfeeding may lower risk of ovarian cancer in women with BRCA gene mutations

Breastfeeding, tubal ligation - also known as having one's "tubes tied" - and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive analysis from a team at the University of Pennsylvania's Basser Research Center for BRCA and the Abramson Cancer Center.

15 May 2014

Findings shed light on evolutionary history of sex chromosomes

In many species, the possession of X and Y chromosomes determines whether an individual develops into a male or female.

14 May 2014

Scientists find protein that controls DNA organization during sperm development

Infertility is generally thought of as a woman's problem. In fact, more than 3 million men across America also experience it.

13 May 2014

Researchers use molecular diagnostic methods to detect cancer

The ABC Medical Center, located in Mexico City, implemented various molecular diagnostic methods that can detect the genetic alterations in several types of cancer, so they can select a personalized therapy for each patient and direct it against the mutated genes that cause disease.

13 May 2014

2 genes work together to drive most lethal forms of prostate cancer

Two genes work together to drive the most lethal forms of prostate cancer, according to new research from the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC).

13 May 2014

Whitehead Institute scientists identify genetic cause of hemifacial microsomia

Whitehead Institute scientists have identified a genetic cause of a facial disorder known as hemifacial microsomia (HFM). The researchers find that duplication of the gene OTX2 induces HFM, the second-most common facial anomaly after cleft lip and palate.

12 May 2014

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

St. Jude Children's Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging.

12 May 2014

Experimental antibody temporarily halts progression of neuroblastoma in children

Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.

9 May 2014

Shift switches pain sensor from cold-sensitive to hot-sensitive

Ice cream lovers and hot tea drinkers with sensitive teeth could one day have a reason to celebrate a new finding from Duke University researchers. The scientists have found a very small change in a single protein that turns a cold-sensitive receptor into one that senses heat.

9 May 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014.

9 May 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Lipids, primarily cholesterol and triglycerides, come from two sources: what is naturally manufactured in the liver and what comes from the intestines through the diet.

From Sanofi 7 May 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

7 May 2014

Study focuses on mutated protein associated with early onset torsion dystonia

A collaborative discovery involving Kansas State University researchers may lead to the first universal treatment for dystonia, a neurological disorder that affects nearly half a million Americans.

7 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

New molecular "clamps" offer powerful new tool for identifying individuals with increased risk of cancer

An international research team has built molecular "clamps" out of DNA that offer a powerful new tool for identifying individuals with an increased risk of cancer.

7 May 2014

Mutation News and Research

A potential epigenetic 'on-off' switch for cancer

Link found between antibiotic use in babies and asthma

Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

Suppressing hyperactivity of calcium channels alleviates familial Alzheimer's disease

Tubal ligation and breastfeeding may lower risk of ovarian cancer in women with BRCA gene mutations

Findings shed light on evolutionary history of sex chromosomes

Scientists find protein that controls DNA organization during sperm development

Researchers use molecular diagnostic methods to detect cancer

2 genes work together to drive most lethal forms of prostate cancer

Whitehead Institute scientists identify genetic cause of hemifacial microsomia

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

Experimental antibody temporarily halts progression of neuroblastoma in children

Shift switches pain sensor from cold-sensitive to hot-sensitive

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

ARIAD provides update on corporate developments, reports Q1 2014 financial results

Study focuses on mutated protein associated with early onset torsion dystonia

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

New molecular "clamps" offer powerful new tool for identifying individuals with increased risk of cancer

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News